The Asia Pacific Liquid Biopsy Market size is expected to grow at a CAGR of 31.23% during the forecast period. As a result, the market size is estimated to be worth USD 893.84 million by 2027 from USD 229.67 million in 2022.
Liquid biopsy is a technique that satisfies patients with the best treatment and also doctors by providing potential screening for disease. In addition, molecular characterization of the tumor can also be done by liquid biopsy. It provides ease of repeat sampling for monitoring genetic changes as the procedure is non-invasive.
Medical communities are extending support for the market, which is acting as a key driver. The liquid biopsy technique is under advancement and is continuously improving, helping drive its adoption in clinical applications. Many new technologies are coming up in the market, such as cell capturing, sample preparation, and DNA amplification, making significant progress. However, the rise in technological competition is acting as a restraint for the market.
The test detects cancer accurately with a simple blood test. Liquid Biopsy has a tremendous positive impact on the fight against cancer by reducing the limitations of traditional biopsies. In India, for the first time in the world, tested 20,000 known cancer pathways at Apollo. Around 73% of patients were detected with ctDNA. In India, Neuroendocrine tumors are slow in growth, but they will spread very quickly. GALLIUM 68 SCAN allows surgeons to find the tumor's location. These techniques will promote the liquid biopsy market in the future. The adoption of advanced technology in the medical sector and the launch of innovative products to diagnose cancer at an early stage is accelerating the market's demand.
In China, there are limitations, and the liquid Biopsy can detect not all cancer biomarkers said by some research institutes. China needs more investigations and further validations. However, the demand is increasing for biomarkers in tumor samples. Researches going on liquid Biopsy in the country will create chances for successful business in the future. Increasing chronic disease incidents and present cancer patients will drive the market in the coming years.
Ministries of Health, Labor, and Welfare in Japan have granted marketing and manufacturing the products used for blood circulating tumor ctDNA molecular testing for colorectal cancer patients. Ongoing research and development programs and the rising number of patients are the major drivers of the liquid biopsy market in Japan.
Australian researchers say that liquid biopsies might be used to treat cancer on a large scale. The Clinical Labs in Australia are proud to aid clinicians and assist patients using advanced technology and a Personalized Medicine approach. It is also beneficial for lung and melanoma patients. So the liquid biopsy market will grow in the future because of the increasing patient count and new player's investments in the market.
In South Korea, biotech companies commercialize the DNA-based liquid biopsy market and enable early cancer detection, precise treatment, and prognostic assessment. The number of patients who have been identified as familial cancer genes with high penetrance will drive the market in the future. Spreading awareness of this market is a challenge for companies. Client relationships and new researches are expected to drive market growth in the forecast period.
This research report on the APAC Liquid Biopsy Market has been segmented and sub-segmented market into the following categories:
By Cancer Type:
By Diagnostic Approach:
Regionally, The Asia-Pacific liquid biopsy market is projected to grow highest during the forecast period, primarily due to the increasing focus of players in this region. In addition, India and China are the emerging countries in the Asia-Pacific region. They are expected to grow fast because of increased market access of each country’s population to healthcare resources.
KEY MARKET PLAYERS:
Some promising companies operating in the APAC Liquid Biopsy Market are Janssen Diagnostics, Qiagen, Rarecells SAS, Silicon Biosystems, SRI International, Myriad Genetics, Natera, Personal Genome Diagnostics, Sysmex Inostics, Trovagene, Exosome Diagnostics, Exosome Sciences, and HansaBiomed OU.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: firstname.lastname@example.org